Lemoxol (Ceftazidime)

Ceftazidime exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This weakens the wall, causing osmotic lysis of susceptible gram‑negative organisms. The drug is bactericidal and retains activity against many β‑lactamase‑producing strains.

The specific dose of Lemoxol is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and should follow the latest clinical guidelines or the product’s prescribing information.

The safety of ceftazidime in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown; therefore, it should be used only if the potential benefit justifies the potential risk to the fetus. Caution is also advised when breastfeeding, as the drug may be excreted in milk.

To place an order, submit an enquiry on the Lemoxol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with earlier‑generation cephalosporins, ceftazidime offers broader coverage against gram‑negative organisms, especially Pseudomonas aeruginosa, and is more resistant to many β‑lactamases. However, it has less activity against gram‑positive cocci than first‑generation agents and may be less effective against some extended‑spectrum β‑lactamase producers, requiring susceptibility testing.

Lemoxol should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Vials should remain in their original packaging until use to maintain sterility. If the product reaches room temperature, it may be used promptly but should be returned to refrigeration if not administered within the recommended time.

Lemoxol is supplied as a sterile solution for parenteral use and is administered by intramuscular or intravenous injection. The route, infusion rate, and dilution are determined by the treating physician based on the infection type and patient condition. Proper aseptic technique and appropriate venous access are essential to prevent contamination.

The most serious adverse reactions include anaphylactic or severe hypersensitivity reactions, Clostridioides difficile‑associated colitis, neutropenia, and renal impairment, particularly when used with other nephrotoxic agents. Early recognition of these events and prompt discontinuation of therapy are critical to minimize morbidity.

Lemoxol is contraindicated in patients with a known hypersensitivity to ceftazidime, other cephalosporins, or any β‑lactam antibiotics. Caution is also advised in individuals with a history of severe allergic reactions, significant renal dysfunction, or those receiving concurrent nephrotoxic drugs, unless the benefits outweigh the risks.